A Single Arm, Multicenter Single Stage Phase II Trial of RAD001 [everolimus] as Monotherapy in the Treatment of Metastatic Non Syndromic Neuro-Endocrine Tumors

Trial Profile

A Single Arm, Multicenter Single Stage Phase II Trial of RAD001 [everolimus] as Monotherapy in the Treatment of Metastatic Non Syndromic Neuro-Endocrine Tumors

Completed
Phase of Trial: Phase II

Latest Information Update: 06 Jul 2017

At a glance

  • Drugs Everolimus (Primary)
  • Indications Neuroendocrine carcinoma
  • Focus Therapeutic Use
  • Acronyms RAMSETE
  • Sponsors Novartis Pharmaceuticals
  • Most Recent Events

    • 27 Feb 2017 Status changed from discontinued to completed.
    • 25 Jan 2017 This trial has been completed in Italy as per European Clinical Trials Database record.
    • 18 Jan 2017 This trial has been completed in Sweden (End date:2016-11-07) as per European Clinical Trials Database record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top